Literature DB >> 2418208

Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations.

I A Holder, J G Naglich.   

Abstract

Flagella preparations of the two antigenic types that make up all the flagella antigens in Pseudomonas aeruginosa were used, individually, to immunize mice. Mice thus immunized were protected when burned and infected with P. aeruginosa. Protection was specific for the flagella antigen of the challenge strain but independent of its somatic antigen. When both antigens were used, together, for immunization, protection was independent of both the flagella and somatic antigen of the challenge strain. These results suggest that a divalent P. aeruginosa 'vaccine' would be of considerable value for immunoprophylaxis in burn patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418208     DOI: 10.1097/00005373-198602000-00003

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  19 in total

1.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

2.  Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum.

Authors:  T R Anderson; T C Montie
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

Review 3.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

4.  Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in mice.

Authors:  T Matsumoto; K Tateda; S Miyazaki; N Furuya; A Ohno; Y Ishii; Y Hirakata; K Yamaguchi
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa.

Authors:  M J Rosok; M R Stebbins; K Connelly; M E Lostrom; A W Siadak
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

6.  Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.

Authors:  W J Landsperger; K D Kelly-Wintenberg; T C Montie; L S Knight; M B Hansen; C C Huntenburg; M J Schneidkraut
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

7.  Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.

Authors:  K Oishi; F Sonoda; A Iwagaki; P Ponglertnapagorn; K Watanabe; T Nagatake; A Siadak; M Pollack; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 8.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

9.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

10.  Serum antibody response to Pseudomonas aeruginosa antigens during corneal infection.

Authors:  M J Preston; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.